The Cancer Dependency Map (DepMap) is committed to systematically accelerating precision cancer medicine by developing comprehensive, large-scale functional datasets that are publicly accessible to the research community. DepMap genomically profiles large panels of human cancer models using WGS, WES and RNA sequencing, and other omics modalities. The project employs genome-wide CRISPR knockout screening and drug sensitivity testing in barcoded cell lines to discover new targets and biomarkers for precision cancer therapy.
Launched in 2017 at the Broad Institute, and building off Project Achilles and CCLE, the DepMap project aimed to provide widespread insights into how specific genes influence cancer cell survival and response to treatments (PMID: 28753430). The DepMap project continues to expand, integrating genomic, transcriptomic, and drug response data, and has become a vital resource for the cancer research community. DepMap’s collaborative approach encourages contributions from researchers worldwide, fostering innovation and discovery in cancer treatment strategies.
The DepMap portal is free to use and includes new data in each DepMap release twice a year in May and November. All of our pipelines and codebases are open source, and our sequencing data is now accessible on dbGaP.
If you have additional questions or suggestions, or to report bugs or data issues, please use our Forum and we’ll be glad to follow up with you!
Join the DepMap community and follow us on:
BlueSky: depmap.org
LinkedIn: Cancer Dependency Map
X: CancerDepMap
